A series of 4,6-substituted-(diaphenylamino)quinazolines as c-Src inhibitors have been prepared and their biological activity has also been evaluated. All the compounds displayed potential antiproliferation activities, with IC50 values ranging from 3.42 μM to 118.81 μM in five human tumor cell lines. Particularly, compound 15 exhibited higher cytotoxicity against the tested five tumor cell lines compared to the other small molecules. Generally, most of these compounds showed selectivity between the A549 cells and the other four cells, according to their corresponding IC50 values. The results obtained from the in vitro enzyme assay indicated compound 15 has remarkable inhibitory activity against c-Src kinase with an IC50 value of 27.3 nM, which is comparable to the control compounds. Furthermore, molecular docking and QSAR study by means of DS 3.5 (Discovery Studio 3.5, Accelrys, Co. Ltd) explored the binding modes and the structure and activity relationship (SAR) of these derivatives.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c3ob41161c | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibiting de novo lipogenesis identifies a therapeutic vulnerability in therapy-resistant colorectal cancer.
Redox Biol
December 2024
Cell and Tumor Biology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India. Electronic address:
A significant clinical challenge in patients with colorectal cancer (CRC), which adversely impacts patient survival, is the development of therapy resistance leading to a relapse. Therapy resistance and relapse in CRC is associated with the formation of lipid droplets (LD) by stimulating de novo lipogenesis (DNL). However, the molecular mechanisms underlying the increase in DNL and the susceptibility to DNL-targeted therapies remain unclear.
View Article and Find Full Text PDFRecent advances of small-molecule c-Src inhibitors for potential therapeutic utilities.
Bioorg Chem
October 2023
School of Pharmacy, Key Laboratory of Elemene Class Anticancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China. Electronic address:
Article Synopsis
- Proto-oncogene tyrosine-protein kinase Src (c-Src) is a key player in cell processes like division and survival, affecting both healthy and cancerous cells through various signaling pathways.
- There is a strong link between c-Src and bone-related diseases, such as osteoporosis, because of its role in osteoclasts and inflammation.
- Recent efforts have led to the development of c-Src inhibitors, with a review highlighting advances in their mechanisms, drug discovery, combination therapies, and ongoing clinical research to inspire further innovation in treatment options.
Focal Adhesion Kinase (FAK) and c-Src Dependent Signal Transduction in Cell Adhesion.
Discov Med
October 2024
Laboratory of Human Anatomy and Cell Biology, Faculty of Health Sciences, Tsukuba University of Technology, 305-8521 Tsukuba, Japan.
This review predominantly acquaints the role of focal adhesion kinase (FAK) and cellular-Src (c-Src) in cell adhesion. Cell adhesion is a crucial phenomenon that causes the cells to interact with the extracellular matrix (ECM) or with each other. There are different proteins involved in cell adhesion including cell adhesion molecules (CAMs)/receptors that are present on the cell surface and various cytoplasmic proteins.
View Article and Find Full Text PDFStructural Basis for Long Residence Time c-Src Antagonist: Insights from Molecular Dynamics Simulations.
Int J Mol Sci
September 2024
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, China.
Article Synopsis
- c-Src plays a crucial role in various cancer signaling pathways and is a key target for cancer treatment.
- Research indicates that extending the residence time of drugs can improve their effectiveness, leading to the development of c-Src antagonists with longer residence times.
- The study utilized molecular dynamics simulations to analyze the binding behavior of different antagonists, identifying a new compound, DFOGS, that enhances binding stability by replacing an unstable amide group, which could lead to better therapeutic outcomes.
Applying molecular hybridization to design a new class of pyrazolo[3,4-d]pyrimidines as Src inhibitors active in hepatocellular carcinoma.
Eur J Med Chem
December 2024
Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Largo Rosanna Benzi 10, 16132, Genoa, Italy.
Hepatocellular carcinoma (HCC) is the most common type of liver solid tumor and the second leading cause of cancer-related deaths worldwide. Although new treatment options have been recently approved, the development of tumor resistance and the poor prognosis for advanced HCC make the current standard of care unsatisfying. In this scenario, the non-receptor tyrosine kinase (TK) c-Src emerged as a promising target for developing new anti-HCC agents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!